ArticleCirculation2018
Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.
Article in Circulation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06247774 (Reducing Heart Failure Risk in Late-Life With Physical Activity), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reducing Heart Failure Risk in Late-Life With Physical Activity: Impact on Cardiac Structure and Function and Proteomic Signatures
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Pooled it
- Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits.Circulation. Heart failure · 2020Pooled it
- Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy.Journal of the American Heart Association · 2024Trial
- Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.Circulation · 2020Trial
- SomaScan proteomics reveals novel biomarkers in the progression of liver cirrhosis to hepatocellular carcinoma.BMC medical genomics · 2026Article
- Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults.Circulation. Genomic and precision medicine · 2026Article
- Diagnostic potential of cryptic exon-derived peptides in serum extracellular vesicles for sporadic amyotrophic lateral sclerosis.Inflammation and regeneration · 2026Article
- Article
- Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic Cohort.International journal of molecular sciences · 2024Article
- Proteomic analysis of cardiovascular disease-associated proteins in Korean patients with moderate-to-severe atopic dermatitis.The World Allergy Organization journal · 2024Article
- Omics-driven investigation of the biology underlying intrinsic submaximal working capacity and its trainability.Physiological genomics · 2023Article
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- Are EPB41 and alpha-synuclein diagnostic biomarkers of sport-related concussion? Findings from the NCAA and Department of Defense CARE Consortium.Journal of sport and health science · 2023Article
- Proteomic biomarkers of Kleine-Levin syndrome.Sleep · 2022Article
- Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods.Science advances · 2022Article
- Proteomic Biomarkers of the Apnea Hypopnea Index and Obstructive Sleep Apnea: Insights into the Pathophysiology of Presence, Severity, and Treatment Response.International journal of molecular sciences · 2022Article
- Recent Developments in Clinical Plasma Proteomics-Applied to Cardiovascular Research.Biomedicines · 2022Review
- Aptamer-based applications for cardiovascular disease.Frontiers in bioengineering and biotechnology · 2022Review
- ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.Journal of hepatology · 2022Article
- Translational precision medicine: an industry perspective.Journal of translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundEmerging proteomic technologies using novel affinity-based reagents allow for efficient multiplexing with high-sample throughput. To identify early biomarkers of myocardial injury, we recently applied an aptamer-based proteomic profiling platform that measures 1129 proteins to samples from patients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned myocardial injury. Here, we examined the scalability of this approach using a markedly expanded platform to study a far broader range of human proteins in the context of myocardial injury.
methodsWe applied a highly multiplexed, expanded proteomic technique that uses single-stranded DNA aptamers to assay 4783 human proteins (4137 distinct human gene targets) to derivation and validation cohorts of planned myocardial injury, individuals with spontaneous myocardial infarction, and at-risk controls.
resultsWe found 376 target proteins that significantly changed in the blood after planned myocardial injury in a derivation cohort (n=20;
conclusionsOur results demonstrate the feasibility of large-scale aptamer multiplexing at a level that has not previously been reported and with sample throughput that greatly exceeds other existing proteomic methods. The expanded aptamer-based proteomic platform provides a unique opportunity for biomarker and pathway discovery after myocardial injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.